Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
45
Participants
Timeline
Start Date
June 30, 2001
Primary Completion Date
August 31, 2007
Conditions
Distal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral CancerRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderUrethral Cancer Associated With Invasive Bladder Cancer
Interventions
DRUG
ixabepilone
Given IV
Trial Locations (1)
02215
Eastern Cooperative Oncology Group, Boston
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00021099 - Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | Biotech Hunter | Biotech Hunter